Nitrofurantoin x 5 days

Phase 2Small molecule

UUniversity of Washington

Nitrofurantoin x 5 days is one of 34 small molecule programs targeting Cystitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CystitisActive, not recruiting

CystitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

51 competitors in Cystitis

#DrugCompanyPhaseTrials

Ivadantin

PProcter and Gamble

Approved

5 2

Monurol

MMeitheal

Approved

4 3

Oxytrol

WWim Janssens

Approved

1 4

Advil

KKenvue Brands

Approved

1 5

Amoxil

GGlobal Antibiotics Research and Development Partnership

Approved

—6

Avycaz

PPhiladelphia Eye Associates

Cipro

2 8

Antibiotics

MMelinta Therapeutics, Inc.

Approved

2 9

Chibroxin

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

1 10

Spectracef

Alnylam Pharmaceuticals

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cystitis1 trial

Short Course Nitrofurantoin for Acute Cystitis

Completed·UUniversity of Washington·Phase 2·NCT00391651·338 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Nitrofurantoin x 5 days. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nitrofurantoin x 5 days compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nitrofurantoin x 5 days. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Washington company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Washington

Nitrofurantoin x 5 days

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cystitis1 trial

References

Drug Info

Quick Facts

Related News